{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:05:12Z","timestamp":1773147912132,"version":"3.50.1"},"reference-count":27,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Introduction: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 \u03bcg\/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.<\/jats:p>\n               <jats:p>Methods: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n = 107), risedronate (n = 59), etidronate (n = 30), and non-bisphosphonate (n = 49). Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months.<\/jats:p>\n               <jats:p>Results: Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment. Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups. BMD responses were similar in all previous antiresorptive groups. Previous etidronate users showed a higher increase at the spine but not at the hip BMD. Duration of previous antiresorptive therapy and lag time between stopping previous therapy and starting teriparatide did not affect the BMD response at any skeletal site. Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide.<\/jats:p>\n               <jats:p>Conclusions: Teriparatide induces positive effects on BMD and markers of bone formation in postmenopausal women with established osteoporosis, regardless of previous long-term exposure to antiresorptive therapies.<\/jats:p>","DOI":"10.1210\/jc.2007-0711","type":"journal-article","created":{"date-parts":[[2007,12,27]],"date-time":"2007-12-27T01:24:49Z","timestamp":1198718689000},"page":"852-860","source":"Crossref","is-referenced-by-count":218,"title":["Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis"],"prefix":"10.1210","volume":"93","author":[{"given":"Steven","family":"Boonen","sequence":"first","affiliation":[{"name":"Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine (S.B.), Universitaire Ziekenhuizen, B-3000 Leuven, Belgium"}]},{"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Medical Research (F.M., C.B., E.V.G., H.O., T.N.), Lilly Research Center, Windlesham GU20 6PH, United Kingdom"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[{"name":"Universita\u0308tsklinik fu\u0308r Innere Medizin (B.O.-P.), Medizinische Universita\u0308t, A-8036 Graz, Austria"}]},{"given":"Maria E.","family":"Simo\u0303es","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Reumatologia (M.E.S.), 1000-154 Lisboa, Portugal"}]},{"given":"Clare","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Medical Research (F.M., C.B., E.V.G., H.O., T.N.), Lilly Research Center, Windlesham GU20 6PH, United Kingdom"}]},{"given":"Emmett V.","family":"Glass","sequence":"additional","affiliation":[{"name":"Department of Medical Research (F.M., C.B., E.V.G., H.O., T.N.), Lilly Research Center, Windlesham GU20 6PH, United Kingdom"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Reproductive Medicine, and Osteoporosis (P.H.), Philipps University, D-35032 Marburg, Germany"}]},{"given":"George","family":"Lyritis","sequence":"additional","affiliation":[{"name":"Department of Orthopedics (G.L.), University of Athens, 10559 Kifissia, Greece"}]},{"given":"Heide","family":"Oertel","sequence":"additional","affiliation":[{"name":"Department of Medical Research (F.M., C.B., E.V.G., H.O., T.N.), Lilly Research Center, Windlesham GU20 6PH, United Kingdom"}]},{"given":"Thomas","family":"Nickelsen","sequence":"additional","affiliation":[{"name":"Department of Medical Research (F.M., C.B., E.V.G., H.O., T.N.), Lilly Research Center, Windlesham GU20 6PH, United Kingdom"}]},{"given":"Eugene V.","family":"McCloskey","sequence":"additional","affiliation":[{"name":"The World Health Organization Collaborating Centre for Metabolic Bone Diseases (E.V.M.), University of Sheffield, Sheffield S3 7HF, United Kingdom"}]}],"member":"80","reference":[{"key":"2020071613362065400_R1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2020071613362065400_R2","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med [Erratum (2005) 165:2120]"},{"key":"2020071613362065400_R3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1359\/jbmr.060314","article-title":"Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.","volume":"21","author":"Ma","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R5","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure.","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R6","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1210\/jc.2004-2489","article-title":"Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial.","volume":"90","author":"Paschalis","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613362065400_R7","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1210\/jc.2002-021988","article-title":"Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment.","volume":"88","author":"Misof","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613362065400_R8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"The effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R10","author":"NICE Guideline TA087 The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women.","year":"2007"},{"issue":"Suppl II","key":"2020071613362065400_R11","first-page":"429","article-title":"Study description and baseline characteristics of the population in the European Forsteo Observational Study (EFOS)","volume":"65","author":"Marin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2020071613362065400_R12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1210\/en.2002-221061","article-title":"New bone formation with teriparatide [human parathyroid hormone-(1\u201334)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.","volume":"144","author":"Ma","year":"2003","journal-title":"Endocrinology"},{"key":"2020071613362065400_R13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071613362065400_R14","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071613362065400_R15","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2020071613362065400_R16","first-page":"S70","article-title":"Comparison of three sequential treatment regimens of teriparatide: final results from the EUROFORS Study","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R17","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/jbmr.5650091002","article-title":"Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results.","volume":"9","author":"Genant","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R18","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1359\/jbmr.1997.12.8.1316","article-title":"Standardization of femur bone mineral density.","volume":"12","author":"Hanson","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2020071613362065400_R19","first-page":"S411","article-title":"Early change in bone turnover following teriparatide (rhPTH 1\u201334) in the EUROFORS Study: influence of prior therapy and association with BMD change at one year","volume":"20","author":"Blumsohn","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins.","volume":"4","author":"Payne","year":"1973","journal-title":"Br Med J"},{"key":"2020071613362065400_R21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood.","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"key":"2020071613362065400_R22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate.","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2020071613362065400_R23","first-page":"S43","article-title":"Response of BMD to 24 months of teriparatide (rhPTH 1\u201334) in patients with and without prior antiresorptive treatment: final results from the EUROFORS Study","volume":"21","author":"Obermayer-Pietsch","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071613362065400_R25","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","article-title":"Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.","volume":"54","author":"Boonen","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"2020071613362065400_R26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone mineral density in men with osteoporosis.","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071613362065400_R27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.","volume":"39","author":"Delmas","year":"2006","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/3\/852\/9055579\/jcem0852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/3\/852\/9055579\/jcem0852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:13:19Z","timestamp":1594944799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/3\/852\/2598527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-0711","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}